June 2017

New Contraindications

Accupril (quinapril hydrochloride) and Accuretic (quinapril hydrochloride/hydrochlorothiazide) are now contraindicated in combination with sacubitril/valsartan due to the increased risk of angioedema.

Angiomax (bivalirudin) is now contraindicated in severe renal impairment (GFR< 30 mL/min) and in dialysis dependent patients.

DBL Amikacin Injection (amikacin sulfate) is now contraindicated in myasthenia gravis.

DBL Sulfamethoxazole 400 mg and Trimethoprim 80 mg Concentrate Injection BP (sulfamethoxazole/trimethoprim) is now contraindicated in patients with a history of drug induced immune thrombocytopenia with use of trimethoprim and/or sulfonamides.

Diane-35 ED, Juliet-35 ED (cyproterone acetate/ethinylestradiol), Petibelle, Yasmin, Yaz, Yaz Flex (drospirenone/ethinylestradiol) and Triquilar ED (levonorgestrel/ethinylestradiol) are now contraindicated with the use of direct acting antiviral (DAA) medicinal products containing ombitasvir, paritaprevir or dasabuvir and combinations of these.

Indocid (indometacin) is now contraindicated in severe hepatic impairment.

Prezista (darunavir) is now contraindicated with elbasvir/grazoprevir and lurasidone.

Stelazine (trifluoperazine hydrochloride) is now contraindicated in uncontrolled cardiac decompensation.

Xifaxan 550 mg (rifaximin) is now contraindicated with intestinal obstruction.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au